<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xsi:schemaLocation="http://www.sec.gov/edgar/thirteenffiler eis_13F_Filer.xsd" xmlns:ns1="http://www.sec.gov/edgar/common" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.sec.gov/edgar/thirteenffiler">
  <schemaVersion>X0202</schemaVersion>
  <headerData>
    <submissionType>13F-HR</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <flags/>
      <filer>
        <credentials>
          <cik>0001703031</cik>
          <ccc>XXXXXXXX</ccc>
        </credentials>
      </filer>
      <periodOfReport>09-30-2025</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <reportCalendarOrQuarter>09-30-2025</reportCalendarOrQuarter>
      <isAmendment>false</isAmendment>
      <filingManager>
        <name>Bain Capital Life Sciences Investors, LLC</name>
        <address>
          <ns1:street1>200 Clarendon Street </ns1:street1>
          <ns1:city>Boston</ns1:city>
          <ns1:stateOrCountry>MA</ns1:stateOrCountry>
          <ns1:zipCode>02116</ns1:zipCode>
        </address>
      </filingManager>
      <reportType>13F HOLDINGS REPORT</reportType>
      <form13FFileNumber>028-18477</form13FFileNumber>
      <provideInfoForInstruction5>Y</provideInfoForInstruction5>
      <additionalInformation>Bain Capital Life Sciences Investors, LLC ("BCLSI") is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iii) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the (a) sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP and (b) the managing member of BCLS Fund III Investments GP, LLC, which is the general partner of BCLS Fund III Investments, LP. The information included on the Information Table with respect to the holdings of Annexon Inc. ("ANNX"), Cabaletta Bio, Inc. ("CABA"), Cidara Therapeutics, Inc. ("CDTX"), NewAmsterdam Pharma Company NV ("NAMS"), Olema Pharmaceuticals, Inc. ("OLMA"), Savara Inc. ("SVRA"), Solid Biosciences Inc. ("SLDB"), X4 Pharmaceuticals, Inc. ("XFOR") and Xilio Therapeutics, Inc. ("XLO") reflect the exercise or conversion of warrants or other convertible securities held by affiliates of BCLSI after giving effect to provisions that prevent the exercise of such securities if the beneficial ownership of such persons would exceed 9.99% of the underlying security following such exercise. As of September 30, 2025, affiliates of BCLSI held an aggregate of 4,474,126 shares of ANNX common stock, 4,260,888 shares of CABA common stock, 2,100,000 shares of CDTX common stock, 10,473,913 ordinary shares of NAMS, 6,696,640 shares of OLMA common stock, 14,789,777 shares of SVRA common stock, 5,034,582 shares of SLDB common stock, 495,991 shares of XFOR common stock and 2,805,413 shares of XLO common stock.</additionalInformation>
    </coverPage>
    <signatureBlock>
      <name>Adam Koppel</name>
      <title>Partner of Bain Capital Life Sciences Investors, LLC</title>
      <phone>617-516-2000</phone>
      <signature>/s/ Adam Koppel</signature>
      <city>Boston </city>
      <stateOrCountry>MA</stateOrCountry>
      <signatureDate>11-14-2025</signatureDate>
    </signatureBlock>
    <summaryPage>
      <otherIncludedManagersCount>12</otherIncludedManagersCount>
      <tableEntryTotal>21</tableEntryTotal>
      <tableValueTotal>1506676329</tableValueTotal>
      <isConfidentialOmitted>false</isConfidentialOmitted>
      <otherManagers2Info>
        <otherManager2>
          <sequenceNumber>1</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-18476</form13FFileNumber>
            <name>Bain Capital Life Sciences Partners, LP</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>2</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-18478</form13FFileNumber>
            <name>Bain Capital Life Sciences Fund, L.P.</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>3</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-20816</form13FFileNumber>
            <name>Bain Capital Life Sciences Investors II, LLC</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>4</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-20814</form13FFileNumber>
            <name>Bain Capital Life Sciences Fund II, L.P.</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>5</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22976</form13FFileNumber>
            <name>BCLS II Investco (GP), LLC</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>6</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22978</form13FFileNumber>
            <name>BCLS II Investco, LP</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>7</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22975</form13FFileNumber>
            <name>Bain Capital Life Sciences III General Partner, LLC</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>8</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22979</form13FFileNumber>
            <name>Bain Capital Life Sciences Fund III, L.P.</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>9</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22968</form13FFileNumber>
            <name>Bain Capital Life Sciences Opportunities III GP, LLC</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>10</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-22966</form13FFileNumber>
            <name>Bain Capital Life Sciences Opportunities III, LP</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>11</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-25138</form13FFileNumber>
            <name>BCLS Fund III Investments GP, LLC</name>
          </otherManager>
        </otherManager2>
        <otherManager2>
          <sequenceNumber>12</sequenceNumber>
          <otherManager>
            <form13FFileNumber>28-25140</form13FFileNumber>
            <name>BCLS Fund III Investments, LP</name>
          </otherManager>
        </otherManager2>
      </otherManagers2Info>
    </summaryPage>
  </formData>
</edgarSubmission>
